underappreci commerci compani chronic
pain manag initi buy pt
commerci stage compani attract market
commerci stage healthcar
technolog compani two product market quell
over-the-count over-the-counter wearabl devic reli neuro-stimul
technolog chronic pain relief dpncheck point-of-car
compani sale believ neurometrix
valuat underappreci current market capit
approxim think current price dec
posit compani may abl move
needl believ plenti room stock
appreci given note quell new gener quell
technolog launch septemb think
could facilit market adopt quell devic given smarter
design smaller size better quell app vs quell origin
devic compani also expect quell launch outsid
us beyond partner importantli compani
ration distribut strategi limit quell highest
profit margin channel e-commerc expect compani gross
margin improv next coupl year think
macro environ address opioid crisi press
need limit opioid use seek altern pain manag
option bode well uptak quell fda commit
cut rate new addict limit opioid access
provid regulatori incent novel product innov believ
favor regulatori environ may spur acceler
product develop invest around opioid crisi
backdrop think neurometrix may interest themat
invest given underappreci valuat believ
compani could easi bolt-on acquisit target compani
gener total sale quell busi
major driver top-line growth point compani
current p/ ratio less well benchmark p/
ratio medic equip suppli industri
csi market websit manag note past year
neurometrix primari busi goal becom profit
oper basi also think commerci
downsid financi risk limit number partnership
gsk agreement enter januari fukuda denshi japanes
distribut partner dpncheck omron medic china
scienta farma mexico view aforement reason
initi buy rate price target
continu next page
definit distribut analyst rate analyst certif disclosur pleas refer page report
quell differenti quell transcutan electr nerv stimul ten medic devic
compris electron devic carri neopren band worn upper calf electrod
attach devic interfac devic skin quell user also option use
smartphon track sleep activ gain person pain therapi quell mobil phone app devic
lightweight worn day night moa involv intens nerv stimul activ
bodi central pain inhibit system produc widespread effect analgesia pain relief nerv stimul activ
brainstem pain center caus releas endogen opioid act primarili delta opioid receptor
reduc pain signal transmiss central nervou system numer ten devic market
sanofi sni rate icyhot smartrelief omron omrni rate alev parent compani bayer
healthcar bayri rate direct therapi although compar ten devic quell price appear
premium think quell differenti number way justifi price point ordinari ten technolog
limit efficaci due devic limit ineffect dose low patient complianc quell incorpor neurometrix
optitherapi technolog collect proprietari approach design optim clinic efficaci nerv stimul
compani believ direct competit quell quell also character high power
autom well digit health integr characterist
next gener quell could propel compani profit view base feedback
custom quell design offer improv origin version includ compact design
smaller origin devic devic comfort worn day think featur could
attract exist new custom may also improv recur order electrod band due
increas custom complianc adher redesign quell app all-new easy-to-us interfac intuit
design easier custom calibr quell precis need smarter power devic
power prior quell devic think improv base feedback real
world custom experi could facilit market adopt quell busi addit compani limit
distribut quell e-commerc amazon rate quellrelief com channel
highest profit margin furthermor note compani quell design ground-up lower cost
improv manufactur result believ oper cost would decreas time increas
commerci adopt quell combin decreas cash consumpt non-dilut financ partnership
think compani tangibl path profit oper basi
macro environ address opioid crisi bode well quell chronic pain widespread affect
million adult billion peopl world-wide recogn one seriou concern
public health fda believ statement fda commission scott gottlieb opioid crisi releas
august underscor agenc focu opioid crisi use tool dispos includ limit opioid
access promot altern option pain manag also point emerg trend space
new asset compani built around medic need macro environ think quell may gain addit
market traction carri risk overdos addict associ opioid medic open-label
post-market clinic studi quell initi neurometrix subject report improv chronic
pain health report reduct use pain medic journal pain research
believ result highli relev reduc opioid addict risk
commerci downsid financi overhang limit partnership think valu proposit
neurometrix primarili driven commerci dynam believ two partnership name gsk fukuda
denshi could mitig commerci downsid financi risk gsk deal includ ex-u right quell technolog
up-front mileston payment point gsk also sell sever over-the-counter pain medic voltaren
ranadol excedrin could gener commerci synergi addit dpncheck distribut japan minimum
sale order
potenti path toward access broader audienc base believ one interest segment market
current captur neurometrix high perform triathlet endur runner accustom spend
consider pursuit athlet passion believ segment market may find tool potenti aid
pain relief recoveri time attract like believ price insensit typic quell custom
toward end believ might make sens neurometrix acquir flex pharma flk rate hotshot product
like avail in-licens given flk public announc intent seek strateg altern sale
compani acquir hotshot would opinion give neurometrix anoth direct-to-consum product allow
introduc quell potenti new market well
model assumpt quell busi model revenu assum address popul
million annual penetr rate new custom quell grow
peak gradual declin due increas competit assum averag cost quell
devic given old quell model still market use quell price
averag cost beyond old model gradual retir market quell instal base assum
return rate in-lin compani record also assum instal base electrod re-ord
annual basi cost per electrod project total quell revenu reach grow
dpncheck revenu model yoy growth given minimum order japanes
distribut partner yoy growth project revenu dpncheck grow
model total revenu grow also model
decreas oper expens guid compani
valuat risk price target base equal weight composit
multipl tax dilut ep discount back npv discount cash
flow discount rate growth rate in-lin commerci stage compani
macro market capit risk invest thesi target price includ failur quell achiev
revenu estim model due market size penetr rate and/or price failur secur capit resourc
fund oper beyond
neurometrix commerci stage healthcar technolog compani two product market
quell over-the-counter wearabl devic chronic pain relief dpncheck point-of-car diabet peripher
neuropathi dpn test neurometrix two strateg partner product compani enter
asset purchas agreement glaxosmithklin ex-u right quell technolog januari
addit fukuda denshi dpncheck japan distributor neurometrix locat waltham
massachusett spun harvard-mit divis technolog
tabl market product neurometrix
quell
quell quell transcutan electr nerv stimul ten medic devic
compris electron devic carri neopren band worn upper calf
electrod attach devic interfac devic skin quell
user also option use smartphon track sleep activ gain person
pain therapi quell app figur devic lightweight worn day
night
quell use high frequenc nerv stimul treat chronic pain high frequenc nerv stimul
establish treatment chronic pain approach avail deep brain stimul
implant spinal cord stimul moa involv intens nerv stimul activ bodi
central pain inhibit system produc widespread effect analgesia pain relief nerv
stimul would activ brainstem pain center caus releas endogen opioid act
primarili delta opioid receptor reduc pain signal transmiss central nervou
system result quell need place directli top pain site
quell may use variou chronic pain type site quell provid relief chronic pain
encompass lower back problem fibromyalgia arthriti pain diabet neuropathi other
believ quell wide market appeal due broad applic studi shai
gozani et al pain relief differ particip proxim
pain group particip distal pain group pain outcom use fixed-sit high
compani present
quell effect chronic pain relief evidenc numer studi
open-label post-market clinic studi quell initi neurometrix subject
report improv chronic pain health report reduct use
pain medic journal pain research figur day quell treatment
respond particip also report clinic signific reduct pain interfer
sleep walk abil
larg retrospect observ studi poster present painweek sep la
vega nv usa figur treatment group particip util quell adequ
dose group show signific improv pain rate refer group
particip util quell low dose group studi period
figur quell significantli improv pain outcom real-world sampl
poster present painweek sep la vega nv usa
quell differenti ten devic
quell ordinari ten devic numer ten devic market
sanofi sni rate icyhot smartrelief omron omrni rate alev parent
compani bayer healthcar bayri rate direct therapi although compar ten
devic quell charg premium per devic think quell differenti number
way justifi price point
ordinari ten technolog limit efficaci due devic limit ineffect dose low
patient complianc hand quell incorpor neurometrix optitherapi technolog
collect proprietari approach design optim clinic efficaci nerv
stimul includ high power electr stimul hardwar precis control
algorithm automat determin therapeut stimul intens compens
nerv desensit autom detect user sleep appropri adjust
stimul level addit quell devic lightweight worn day night
compani believ direct competit quell
quell also character high power autom well digit health
figur also summar technic comparison quell over-the-counter ten product
figur quell differenti over-the-counter ten product market
newli launch third gener quell could facilit market adopt
quell offer benefit older version origin quell clear fda made
commerci avail june quell third gener quell devic
launch septemb accord compani approxim
quell devic plu electrod accessori ship custom follow commerci launch
end base feedback custom quell design offer
improv origin version includ compact design smaller
origin devic devic comfort worn all-day think featur could
attract exist new custom may also improv recur order electrod
band due increas custom complianc adher redesign quell app all-new
easy-to-us interfac intuit design easier custom calibr quell
precis need smarter power devic power prior quell
devic think improv base feedback real world custom
experi could facilit market adopt quell busi
new patent issu expand protect quell wearabl technolog also note
neurometrix announc coupl new patent quell wearabl technolog patent
cover compani novel neurostimul technolog effici tradit
rate amazon rate may suggest better custom experi quell
also look custom review amazon quell quell indic
custom experi market traction note dec quell classic receiv
custom review star rank household amazon best seller
quell receiv custom review star rank household
amazon best seller
improv gross margin uptick revenu could propel
compani toward profit
distribut channel shift highest profit margin channel quell distribut via
e-commerc direct respons televis variou retail merchandis healthcar profession
other distribut also support televis social media promot howev market
adopt quell fast compani expect result neurometrix identifi sever
key engag step acceler uptak expect see improv perform
compani also limit distribut quell e-commerc amazon
quellrelief com channel highest profit margin think switch help
improv overal gross margin compani compani also plan distribut
product e-commerc signific increas figur addit note
compani quell design ground-up lower cost improv
manufactur result believ oper cost would decreas time increas
commerci adopt quell combin decreas cash consumpt non-dilut
financ partnership think compani tangibl path profit oper
basi
figur neurometrix plan shift distribut channel highest margin channel
keyword search point quell visibl
sinc compani switch distribut channel e-commerc also perform keyword use
pain relief devic search googl rate amazon chrome browser search date
dec quell show front page search figur think high visibl
product internet search could land quell broader radar screen potenti custom
particularli activ seek altern pain relief option
figur keyword pain relief devic search googl amazon point quell visibl
amazon chrome browser dec sort featur
macro environ opioid epidem bode well quell
opioid crisi one seriou public health issu opioid epidem gain
nation spotlight due increas overdos death recent year figur believ
press need altern pain manag opioid opioid crisi
caus misus addict opioids-includ prescript pain reliev heroin
synthet opioid fentanyl american die result opioid
overdos year estim million peopl suffer substanc use
disord relat prescript opioid pain reliev suffer heroin use disord
mutual exclus common prescript opioid
oxymorphon morphin codein fentanyl
figur opioid epidem number
compani present nation institut drug abus websit
statement fda commission scott gottlieb opioid crisi
statement underscor fda dedic address opioid crisi august
fda releas commission statement agenc on-going work forc address
opioid crisi document outlin step agenc take includ cut rate
new addict ration prescrib opioid amount dispens step
enforc market sale illicit opioid undertak new effort promot novel
product innov particular point regulatori new pathway develop safe
effect treatment addict lower barrier innov treatment meet gold
standard note document think favor regulatori environ may spur
innov well heighten interest invest anti-opioid crisi space addit stricter
access opioid medic facilit uptak non-opioid altern
acceler devic develop prevent treat opioid use fda one
fda attempt address one profound public health crise face countri agenc
launch innov challeng may spur develop medic devic includ
diagnost test digit health technolog see figur note among applic
select challeng two product pain therapi per new program select
applic work directli agenc acceler develop expedit market
applic review innov product similar occur breakthrough devic
program believ support fda catalyz devic field may attract investor
figur list applic select fda innov challeng devic
prevent treat opioid use disord
invest altern pain manag gain momentum
new asset compani built around medic need opioid addict note
seem emerg trend develop novel non-opioid therapi around opioid crisi
highlight sever exampl illustr point inhibitor current develop
vertex buy acut neuropath pain treatment whose moa differ opioid-
relat pain medic start-up centrexion privat led former rate ceo
jeff kindler phase painkil program call synthet ultra-pot pure form
capsaicin activ ingredi chili pepper rate recent bought
hydra bioscienc privat asset pain target ion channel instead opioid receptor expand
effort next-gen pain drug addit point figur list current pipelin
chronic pain non-opioid target highlight think heighten interest investor
regul biopharmaceut compani may collect favor capit alloc space
could posit neurometrix interest vehicl captur valu either top-line growth
potenti specif although hard quantifi effect believ focu
opioid crisi regul public may give media attent altern pain
manag option drive need non-opioid treatment custom healthcar
figur pipelin treatment chronic pain
rate
rate
allergan plc rate
merck co inc
slno rate
cyclooxygenas sodium
inc ptx rate
quell attract altern opioid pain medic
quell offer benefit opioid pain medic figur non-invas devic note
quell carri safeti baggag associ opioid pain medic need
prescript instanc oxycodon caus nausea vomit constip drowsi
overdos lead pass slow heartbeat troubl breath none occur use
quell
figur quell vs pain relief option
current market capit attract commerci compani
neurometrix valuat attract note neurometrix gener sale figur
revenu first three quarter shipment devic electrod
increas yoy sinc launch figur also point current market cap
compani approxim dec close p/ ratio less
well benchmark p/ ratio medic equip suppli industri csi market
websit addit stock trade past coupl month lower
total cash-per-share book value-per-share data yahoo financ dec
market chronic pain enorm chronic pain widespread affect million adult
unit state billion peopl world-wide global market pain manag drug
devic alon valu billion estim out-of-pocket spend chronic pain
billion per year compani believ quell address market million custom
argu neurometrix would captur sizabl portion think given market size
grow trajectori quell still plenti room grow
commerci downsid financi risk limit partnership think valu
proposit neurometrix primarili driven commerci dynam believ two
partnership name gsk fukuda denshi may mitig commerci downsid provid non-dilut
financ compani gsk deal includ ex-u right quell technolog up-front
mileston payment point gsk also sell lead over-the-counter pain medic voltaren
ranadol excedrin gener commerci synergi addit dpncheck distribut japan
minimum order
capit structur also note small cap compani neurometrix debt compani
cash cash equival septemb addit neurometrix equiti
compos common convert prefer share insignific warrant
figur sale shipment sinc launch quell
quell busi model revenu assum address popul
million annual penetr rate new custom quell grow
peak gradual declin due increas competit
assum averag cost quell devic given old quell model still
market use quell price averag cost beyond old
model gradual retir market quell instal base assum return rate in-lin
compani record also assum instal base electrod re-ord annual basi
cost per electrord project total quell revenu reach grow
dpncheck revenu model yoy growth given
minimum order japanes distribut partner yoy growth project
revenu dpncheck grow model total revenu
grow also model decreas oper expens guid
compani
valuat risk
price target base equal weight composit
multipl tax dilut ep discount back npv
discount cash flow discount rate growth rate in-lin
commerci stage compani macro market capit risk invest thesi
target price includ failur quell achiev revenu estim model due market size
penetr rate and/or price failur secur capit resourc fund oper
beyond
except per share valu
revenu
revenu
revenu
net incom avail common
except patient number
unit quell devic ship thousand
quell devic
quell instal base return rate thousand
numer electrod re-orders/year
quell electrod re-ord thousand
electrod
except per share valu
discount
sensit ep estim
discount
chang work capit
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori neurometrix inc nuro-u
rate price target histori inc axsm-u
rate price target histori inc coll-u
rate price target histori inc vrtx-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl decemb
 wainwright co llc firm member finra sipc regist broker-deal
andrew fein li wang watsek alicia yin ph certifi view express report accur
reflect person view subject secur issuer discuss part compens
directli indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur neurometrix
inc inc inc includ without limit option right warrant
futur long short posit
novemb neither firm affili benefici class common equiti secur
neurometrix inc inc inc
neither research analyst firm materi conflict interest research analyst know
reason know time public research report
research analyst firm and/or research analyst household financi interest secur
includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens neurometrix inc inc vertex
pharmaceut inc invest bank servic within twelv month seek compens
compani mention report invest bank servic within three month follow public research
firm affili receiv compens inc invest bank servic within
twelv month seek compens compani mention report invest bank servic
within three month follow public research report
 wainwright co llc manag co-manag public offer secur inc
firm make market neurometrix inc inc inc vertex
pharmaceut inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
